We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03711188
Recruitment Status : Completed
First Posted : October 18, 2018
Last Update Posted : April 7, 2022
Information provided by (Responsible Party):
Immodulon Therapeutics Ltd

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 2, 2021
Actual Study Completion Date : December 2, 2021
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 January 18, 2023